(C) B2Bioworld 2011 - sample to sequenceCustom Sequencing Markets

October 2011. The technological jump into next-generation sequencing brings considerable uncertainties to the business of custom sequencing, says Bruno Poddevin responsible for Eurofins' global genomic services, in the exclusive interview with B2Bioworld.

How can service providers cope with it? What exactly is the size of the market accessible to private companies today? How should daily operations take up opportunities? Is it an option to install laboratories in India or China to service customers in Europe or in the US? An estimate of market size, critical evaluation of segments and opportunities in different geographies for the next two to three years. About errors of the past and lessons learned.

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 8 pages

Full Company License enquire here

Back to section

Related Editorial Articles

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, past Chief Technology Officer Life Sciences at Tecan on strengths and weaknesses of electrowetting development, weaknesses of competitors like Illumina. Prospects of clinical microfluidics

Metrics for Disease, Health, and Wellness
A systems look at DNA sequencing for personalized medicine by Dr Leroy Hood, President Institute for Systems Biology, Seattle

Instrument Automation: We need the users, and users have to adopt it
A Global View on Interconnectivity, Quality, Harmonisation of Standards of Laboratory Automation and Biomanufacturing by Oscar-Werner Reif, Member of Board Sartorius Stedim Biotech S.A.

Laboratory Automation: Everyone Re-invents The Wheel
Michael Collasius, Vice President Automated Systems Qiagen NV, on industry-wide standards for laboratory instruments

Handling Suppliers of Mass Spectrometers Delicately
Michael P. Myers, International Centre for Genetic Engineering and Biotechnology, Trieste (IT) tells how he is avoiding to get trapped by manufacturers of mass spectrometers and their strategies to fend off competitors with proprietary data formats

Thermo Fisher’s BRIMS-Strategy Under Testing

Electrophoresis in Proteomics
– Some Common Pitfalls and Ways to Avoid Them

Easier Access to Patent Claims Encoded in Chinese
EPO catalyzes innovation of intercontinental IP systems. Questions about Russia’s intentions

Patient-centered Precision Care
Michael Christman, President of Coriell Institute on turning research on human genotyping into healthcare routine and attracting payors

Is that worth a dollar, or a million dollars?
Ed Torres, Managing Director of Lilly Ventures on the Fund’s input to Eli Lilly’s business development